1. Emodin targets mitochondrial cyclophilin D to induce apoptosis in HepG2 cells
- Author
-
Baitao Wang, Dian He, Lifang Zheng, Ling Zhang, Hongli Liu, Kun Li, and Jiazhong Li
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Emodin ,MAP Kinase Signaling System ,Apoptosis ,Mitochondrion ,Biology ,Cyclophilins ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Epidermal growth factor ,Cell Line, Tumor ,Cyclosporin a ,Humans ,Pharmacology ,chemistry.chemical_classification ,Reactive oxygen species ,Activator (genetics) ,Hep G2 Cells ,General Medicine ,Mitochondria ,Cell biology ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Cyclosporine ,Reactive Oxygen Species ,Cyclophilin D - Abstract
Emodin has demonstrated potent anticancer activity in human hepatocarcinoma cells and animal models, however, the cellular targets of emodin have not been fully defined. Here we report that emodin induces the dysfunction of mitochondria and the apoptosis in HepG2 cells through an enrichment in mitochondria. Specifically, A mitochondrial matrix protein (cyclophilin D, CyPD) is involved in emodin-induced apoptosis, and the inhibitor of CyPD (cyclosporin A) could almost completely suppressing the apoptosis; Moreover, as the expression of CyPD could be effectively inhibited by antioxidant N-acetyl-l-cysteine and epidermal growth factor (the activator of ERK), reactive oxygen species and ERK might be involved in the relevant role of CyPD. A further molecule-docking discloses the existence of three hydrogen-bonds in CyPD-emodin complex. Thus, target localization and CyPD in mitochondria provides an insight into the action of emodin in the treatment of liver cancer.
- Published
- 2017